Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy Trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD)

NCT03790709 is registered in ClinicalTrials.gov with Anavex Life Sciences Corp. as lead sponsor.

NCT NCT03790709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03790709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy Trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD)
Lead sponsor
Anavex Life Sciences Corp.
Phase
Phase 2/3
Overall status
Completed
Start date
July 3, 2018
Completion date
June 30, 2022
Enrollment
509 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease